[go: up one dir, main page]

PE20090895A1 - Derivados de triazol como inhibidores de la jak quinasa - Google Patents

Derivados de triazol como inhibidores de la jak quinasa

Info

Publication number
PE20090895A1
PE20090895A1 PE2008001287A PE2008001287A PE20090895A1 PE 20090895 A1 PE20090895 A1 PE 20090895A1 PE 2008001287 A PE2008001287 A PE 2008001287A PE 2008001287 A PE2008001287 A PE 2008001287A PE 20090895 A1 PE20090895 A1 PE 20090895A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrazole
alkenyl
methyl
jak
Prior art date
Application number
PE2008001287A
Other languages
English (en)
Inventor
Lynsie Almeida
Brian Aquila
Claudio Edmundo Chuaqui
Huiping Guan
Shan Huang
Stephanos Ioannidis
Michelle Lamb
Bo Peng
Jie Shi
Mei Su
Quibin Su
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090895(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090895A1 publication Critical patent/PE20090895A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDO A UN COMPUESTO DERIVADO DE TRIAZOL DE FORMULA (I): DONDE EL ANILLO A ES HETEROCICLILO OPCIONALMENTE SUSTITUIDO SOBRE EL C CON UNO O MAS R2; EL ANILLO B ES SELECCIONADO DE CARBOCICLO Y HETEROCICLILO OPCIONALMENTE SUSTITUIDO SOBRE EL C CON UNO O MAS R4; X ES -O-, -NH- Y -S-; R1 ES HALO, -CN, ALQUILO(C1-C6), ENTRE OTROS; R2 ES -CN, ALQUILO(C1-C6), ALQUENILO(C2-C6), ENTRE OTROS; R3 ES ALQUILO(C1-C6), ALQUENILO(C2-C6); ALQUINILO(C2-C6), ENTRE OTROS; R4 ES ALQUILO(C1-C6), ALQUENILO (C2-C6), CARBOCILILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (S)-N2-(1-(5-FLUOROPIRIDIN-2-IL)ETIL)-N4-(5-METIL-1H-PIRAZOL-3-IL)-6-(4-METILPIPERAZIN-1-IL)-1,3,5-TRIAZINA-2,4-DIAMINA, (S)-N2-(1-(5-FLUOROPIRIMIDIN-2-IL)ETIL)N4-(5-METIL-1H-PIRAZOL-3-IL)-6-MORFOLIN-1,3,5-TRIAZINA-2,4-DIAMINA, 4-(1-(5-FLUOROPIRIDIN-2-IL)ETOXI)-N-(5-METIL-1H-PIRAZOL-3-IL)-6-MORFOLIN-1,3,5-TRIAZIN-2-AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA FORMULACION Y A UN METODO DE PREPARACION. DICHO COMPUESTO TIENE ACTIVIDAD INHIBITORIA DE JAK QUINASA Y ES UTIL EN EL TRATAMIENTO DE TRASTORNOS MIELOPROLIFERATIVOS Y EL CANCER
PE2008001287A 2007-07-31 2008-07-31 Derivados de triazol como inhibidores de la jak quinasa PE20090895A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95315807P 2007-07-31 2007-07-31

Publications (1)

Publication Number Publication Date
PE20090895A1 true PE20090895A1 (es) 2009-08-08

Family

ID=40304964

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001287A PE20090895A1 (es) 2007-07-31 2008-07-31 Derivados de triazol como inhibidores de la jak quinasa

Country Status (6)

Country Link
AR (1) AR069899A1 (es)
CL (1) CL2008002243A1 (es)
PE (1) PE20090895A1 (es)
TW (1) TW200906818A (es)
UY (1) UY31254A1 (es)
WO (1) WO2009016410A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2755394C (en) 2009-03-13 2021-10-19 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
AU2010259002B2 (en) * 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
EP2440053A4 (en) * 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
KR101712035B1 (ko) 2009-06-29 2017-03-03 아지오스 파마슈티컬스 아이엔씨. 치료용 화합물 및 조성물
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CN108451955B (zh) 2011-05-03 2022-02-01 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AR091858A1 (es) * 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
NZ706999A (en) 2012-10-15 2018-12-21 Agios Pharmaceuticals Inc Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
CN105517996B (zh) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
JP6529492B2 (ja) 2013-07-11 2019-06-12 アジオス ファーマシューティカルズ， インコーポレイテッド 癌の処置のためのｉｄｈ２突然変異体阻害剤としての２，４−または４，６−ジアミノピリミジン化合物
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
AU2015229214B2 (en) 2014-03-14 2019-07-11 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
ES2708344T3 (es) 2015-01-16 2019-04-09 Bayer Cropscience Ag Procedimiento para la preparación de hidrocloruro de 4-cianoperidina
EP4344703A1 (en) 2015-06-11 2024-04-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
MX390531B (es) 2015-10-15 2025-03-20 Servier Lab Terapia de combinacion para tratar tumores malignos.
MA43000B1 (fr) 2015-10-15 2021-11-30 Celgene Corp Polythérapie pour le traitement de tumeurs malignes
EP3676264A1 (en) * 2017-08-28 2020-07-08 Acurastem Inc. Pikfyve kinase inhibitors
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CA3103624A1 (en) * 2018-06-22 2019-12-26 Aduro Biotech, Inc. Triazine compounds and uses thereof
CN109020951B (zh) * 2018-08-24 2020-06-02 大连理工大学 含三取代三聚氯氰的萘酰亚胺类衍生物及其合成方法和应用
CN114761013A (zh) 2019-09-27 2022-07-15 迪斯克医药公司 治疗骨髓纤维化和相关病症的方法
JP2023528223A (ja) 2020-05-13 2023-07-04 ディスク・メディシン・インコーポレイテッド 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁（上海）医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030032035A (ko) * 2000-09-15 2003-04-23 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물
MXPA03005610A (es) * 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
US7179826B2 (en) * 2002-03-15 2007-02-20 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US20080287437A1 (en) * 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
HRP20120824T1 (hr) * 2005-10-28 2012-11-30 Astrazeneca Ab Derivati 4-(3-aminopirazol) pirimidina za uporabu kao inhibitori tirozin kinaze u lijeäśenju karcinoma

Also Published As

Publication number Publication date
WO2009016410A3 (en) 2009-07-02
CL2008002243A1 (es) 2009-08-21
WO2009016410A2 (en) 2009-02-05
AR069899A1 (es) 2010-03-03
TW200906818A (en) 2009-02-16
UY31254A1 (es) 2009-04-30

Similar Documents

Publication Publication Date Title
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20141681A1 (es) Inhibidores de btk
PE20140934A1 (es) Derivados de pirazol
PE20150621A1 (es) Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20131377A1 (es) Triazina-oxadiazoles
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
PE20050681A1 (es) PIRIDO[2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
PE20090887A1 (es) DERIVADOS DE 1H-PIRAZOL-[3,4-d]-PIRIMIDINA, 9H-PURINA Y 7H-PIRROL-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASA P70 S6
NZ591449A (en) Picolinamide derivatives as kinase inhibitors
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
PE20100087A1 (es) Compuestos y composiciones como inhibidores de cinasa
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
CL2012001366A1 (es) Compuestos derivados de carboxamida n-((2-morfolino-5-ariltiazol-4-il)metil), moduladores de receptores nicotinicos alfa 7; composicion farmaceutica; proceso para prepararla; combinacion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, demencia, esquizofrenia, enfermedad de parkinson, entre otras.
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida

Legal Events

Date Code Title Description
FD Application declared void or lapsed